If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
195
results.
Updated on
25/12/2025 [07:33:00]
Results 175 to 195 of 195
Absstract of: CN120210101A
The invention discloses an inflammatory bowel disease model, a construction method and application thereof and a drug evaluation method based on the inflammatory bowel disease model, and belongs to the technical field of inflammatory bowel disease model construction. A highly bionic intestinal crypt-villus three-dimensional structure is formed based on self-organization of an intestinal cell line C2BBe1, the intestinal crypt-villus three-dimensional structure and a DMEM complete medium containing dextran sulfate sodium are added into an upper chamber of a double-layer culture chamber Transwell, the DMEM complete medium is added into a lower chamber of the double-layer culture chamber Transwell, culture is performed for 2 days, and the inflammatory bowel disease model is obtained. The method takes effect quickly and is highly simulated, the obtained model can simulate the space-time dynamic development process of intestinal inflammation molecular characteristics, and the natural recovery model and the drug treatment model constructed based on the model can provide a brand new platform for researching an inflammation regression mechanism and a drug intervention effect.
Absstract of: CN120214122A
The invention provides application of alpha-ZAL in screening the risk of Crohn disease, and belongs to the technical field of biochemical detection. According to the present invention, the endocrine disrupter alpha-zeenol is adopted as the marker for screening the risk of the Crohn disease, the high performance liquid chromatography-tandem mass spectrometry detection technology is adopted to detect the endocrine disrupter, and the endocrine disrupter is prepared into the kit for the risk analysis of the Crohn disease.
Absstract of: WO2025136105A1
The invention relates to methods of predicting a response of an individual suffering from an inflammatory bowel diseases, such as Crohn's disease (CD) to treatment with a Tumor Necrosis Factor alpha inhibitor (TNFα-i). The invention further relates to anti-TNFα therapy, for treating an individual who was predicted to positively respond to said therapy by the methods of the invention, and to an integrin α4β7 blocking agent, or interleukin (IL)-12 and IL-23 blocking agent, for treating an individual who was predicted not to respond to anti-TNFα therapy by the methods of the invention.
Absstract of: CN120195385A
The invention belongs to the technical field of biomedicine, and particularly relates to application of xylulose-5-phosphoric acid as an inflammatory bowel disease biomarker with intestinal fibrosis characteristics. It is found for the first time that xylulose-5-phosphoric acid is remarkably increased in a biological sample of a patient with the inflammatory bowel disease with the intestinal fibrosis characteristic, and the expression level of xylulose-5-phosphoric acid in the biological sample of the patient with the inflammatory bowel disease with the intestinal fibrosis characteristic is in a positive correlation relation with the occurrence degree of the intestinal fibrosis. The discovery provides an important therapeutic target for predicting or evaluating whether a subject suffers from the inflammatory bowel disease with the intestinal fibrosis characteristic by using the xylulose-5-phosphoric acid as the inflammatory bowel disease biomarker with the intestinal fibrosis characteristic.
Absstract of: CN120198599A
The invention relates to an intelligent endoscope image evaluation method for ulcerative colitis, and the method comprises the steps: synchronously collecting video streams and three-dimensional point cloud data of a colonic mucosa through an endoscope system equipped with a structured light depth sensor, and constructing a three-dimensional coordinate system based on a colon anatomy trend; based on the three-dimensional point cloud data, constructing a complex topological structure on the surface of the colonic mucosa, and calculating a continuous homology feature set of the lesion area; and based on the persistent homology feature set, constructing a multi-scale graph neural network model of ulcerative colitis and Crohn disease specificity. By implementing the scheme, the structural and topological modeling of the colon mucosa lesion area can be realized, and the morphological characteristic difference between ulcerative colitis and Crohn's disease can be effectively captured. The multi-scale graph neural network fuses macroanatomical segmentation and micropathology features, efficient distinguishing of continuous and jumping lesions is achieved, finally, an intelligent and visual endoscope evaluation report is generated, and the accuracy and real-time performance of auxiliary diagnosis in an operation are improved.
Absstract of: CN120174078A
The invention provides a composition for diagnosing Crohn's disease, a kit and application of an enhancer RNA44345 in preparation of the composition, and relates to the technical field of biological medicines. The invention relates to an application of an enhancer RNA44345 in preparation of a composition for diagnosing Crohn's disease, and the enhancer RNA44345 is used as a detection marker of the composition for diagnosing Crohn's disease. The enhancer RNA44345 serves as a detection marker of the composition for diagnosing the Crohn disease, the sensitivity is 74.6%, the specificity is 81.7%, the sensitivity and the specificity are high, and a new tool can be provided for early diagnosis and prognosis evaluation of the Crohn disease.
Absstract of: WO2025128818A1
Aspects of the disclosure provides composition and methods for treating a subject having inflammatory bowel disease, the method comprising administering to the subject a hemojuvelin (HIV) antagonist (e.g., anti-HJV antibody).
Absstract of: US2025197388A1
The disclosure provides pharmaceutical compositions comprising a therapeutically effective amount of compound (A), compound (B), compound (C), compound (D), compound (E), compound (F), compound (G), compound (H), compound (J), compound (K), compound (L), compound (M), compound (N), compound (O), compound (P), or compound (Q) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient: Also provided are dosage units comprising one or more of compound (A), compound (B), compound (C), compound (D), compound (E), compound (F), compound (G), compound (H), compound (J), compound (K), compound (L), compound (M), compound (N), compound (O), compound (P), or compound (Q) or the pharmaceutical compositions described herein, methods of treating an inflammatory bowel disease in a subject in need thereof, or methods of modulating an inflammatory bowel disease marker in a subject in need thereof.
Absstract of: NZ730490A
Described herein are methods and systems for distinguishing diarrhea predominant irritable bowel syndrome (D-IBS) from inflammatory bowel disease (IBD) and celiac disease. The methods and systems can utilize the detection of anti-vinculin antibodies and anti-CdtB antibodies to distinguish IBS from IBD and celiac disease. Further described are methods for selecting a therapy to treat IBS, IBD or celiac disease.
Absstract of: JP2025090706A
To solve the problem in which an inflammatory bowel disease (IBD) can be an existential threat to animals; protein losing enteropathy associated with IBD results in the loss of endogenous hemostatic albumin and immunoglobins through a degraded gut barrier; it is therefore desirable to provide a pet food composition which may beneficially affect animals suffering from IBD, such as by increasing the circulating protein of the animal, increasing biomarkers associated with health, and/or modifying the gut microbiome.SOLUTION: There are provided pet food compositions comprising: about 7 wt.% or more, based on the total weight of the pet food composition, of an amino acid component comprising, lysine, betaine, and a glutamic acid and/or a salt of them; and about 3.3 wt.% or more, based on the total weight of the pet food composition, of a fatty acid component comprising a fatty acid having an aliphatic tail of 6 to 12 carbon atoms and/or an omega-3 fatty acid.SELECTED DRAWING: Figure 1A
Absstract of: CN120164631A
The invention discloses a follow-up visit management system for an inflammatory bowel disease patient, and relates to the technical field of medical management. Comprising a patient management module which is in dynamic butt joint with a hospital information system, synchronizes patient data and endoscopic examination results in real time through an HL7 protocol, and establishes an electronic file containing an inflammatory bowel disease specificity tag; the diagnosis and treatment result module is used for storing structured data with temporal markers, including medication time sequences recorded by three groups of timestamps, administration routes and drug categories, auxiliary examination results accompanied with digestive tract pathological section images and hidden space feature vectors extracted from the images through a convolutional neural network; and the diet module is used for carrying out multi-level classification on diet photos uploaded by the patient through an image recognition unit based on MobileNetV3, and outputting food types and intake estimated values. According to the invention, by integrating the multi-dimensional data of the patient, the disease development trend is predicted, and personalized follow-up visit management is provided.
Absstract of: WO2025121789A1
The present invention relates to an inflammatory bowel disease model derived from induced pluripotent stem cells and a method for producing same. The inflammatory bowel disease model simulates stable intestinal epithelial cells from induced pluripotent stem cells and remarkably exhibits the expression of inflammation-related genes according to the occurrence and improvement of inflammatory bowel disease, and thus can be effectively used for evaluating the efficacy of a drug for treating inflammatory bowel disease.
Absstract of: CN120138126A
The invention relates to the technical field of disease detection kits, in particular to application of an scrK gene as a target spot to preparation of a kit or a medicine for detecting or treating enteritis related to abnormal fructose metabolism. The detection of the abnormal fructose metabolism related enteritis comprises the following steps: detecting the expression level of an scrK gene of a sample to be detected, and judging whether the source of the sample to be detected has abnormal fructose metabolism related enteritis (such as inflammatory bowel disease) or not according to a detection result and the fructose content, or judging the severity of the enteritis related to abnormal fructose metabolism from the sample to be detected. A target spot (scrK gene) of enteritis related to abnormal fructose metabolism is found through research, a plurality of detection kits applied to abnormal fructose metabolism diseases such as inflammatory bowel diseases and intestinal inflammation-cancer transformation process can be developed based on detection of the gene, the cause of occurrence or aggravation of enteritis is defined, and the application prospect is wide. And direct evidence is provided for accurate diagnosis and treatment.
Absstract of: CN120142669A
The invention discloses a serum protein and metabolism marker for diagnosis or auxiliary diagnosis of colorectal cancer or ulcerative colitis, the serum protein and metabolism marker comprises 10 serum protein markers or/and 11 serum metabolites, the serum protein markers comprise APOA4, APOC3, APOF, C4B, CLEC3B, FERMT3, NID2, RAB11B, CRP and CSF1, and the serum metabolism markers comprise LysoPA 18: 2, LysoPA 18: 3, Valproic acid, LysoPA 16: 0, Cis-4-DGTS 12: 0, Choline, Acylcarnitine 19: 3 and Cis-4-. By screening differentially expressed serum proteins and metabolites of patients with colorectal cancer and ulcerative colitis, machine learning is utilized to screen markers and construct a diagnosis model, so that diagnosis and auxiliary diagnosis of colorectal cancer are facilitated. In addition, the invention further discloses application of the serum protein and the metabolic marker, and the serum protein marker and the serum metabolic marker are used independently or in a combined mode.
Absstract of: CN120138155A
The invention discloses a method for analyzing and identifying an inflammatory bowel disease related oral cancer biomarker, and belongs to the technical field of bioengineering.The method comprises the following steps that 1, IBD whole genome correlation research summary data is obtained; 2, analyzing a causal relationship between IBD and the oral cancer by using a Mendel randomization method, and determining IBD related genes; 3, collecting an oral cancer tissue sample, and carrying out single-cell RNA sequencing; according to the invention, single-cell RNA sequencing is carried out on an oral cancer specimen, and a cell cluster and a gene expression mode are described. Cell clusters and types are displayed by using t-SNE and UMAP, key modes of gene expression are defined by using a lattice diagram, and pathways related to NFKBIA expression are analyzed through GSEA. The experimental result explains the cell heterogeneity and gene expression kinetics in the oral cancer disease progression process, and reveals possible therapeutic targets related to IBD.
Absstract of: CN120138119A
The invention provides a method for evaluating the intervention effect of probiotics based on baseline intestinal microbiome robustness, which comprises the following steps: collecting a sample of a mouse colitis model for metagenome sequencing, analyzing the robustness of the intestinal microbiome of an individual in a baseline period, and evaluating the intervention effect of the probiotics, the mouse colitis model comprises a control group, a model group and a probiotic group. Experimental results show that based on the robustness of the host baseline microbiome, the curative effect of the probiotic intervention treatment on the IBD can be more accurately deduced. The prediction effect of the robustness of the intestinal microorganisms in the baseline period on probiotic treatment is elaborated, and a theoretical basis and technical support are provided for optimizing a probiotic treatment scheme in clinical practice.
Absstract of: WO2025120137A1
The present invention relates to the field of mucins and mRNA isoforms thereof, more in particular the use of mucins and mRNA isoforms in subjects suspected having an intestinal disorder. Provided herein is an in vitro method for determining the presence of barrier damage to the intestinal tract and/or prediction of therapy response and recovery thereto by determining the expression of at least 3 mRNA isoforms originating from genes selected from the list comprising: MUC1, MUC2, MUC3A, MUC4, MUC5AC, MUC5B, MUC6, MUC12, MUC12-AS1, MUC13, MUC16, MUC17, MUC19, MUC20 or an overlapping transcript or a pseudogene thereof.
Absstract of: US2025191684A1
Example embodiments relate to identity-by-descent (IBD) relatedness based on focal and reference segments. An example method includes determining, by a services platform based on personal information of a focal individual, a focal string. The method also includes retrieving, by the services platform from a reference database, a reference string of a reference individual. Additionally, the method includes computationally identifying, by the services platform, IBD segments between the focal string and the reference string. Further, the method includes determining, by the services platform and based on the merged set of IBD segments, a degree of relatedness between the focal individual and the reference individual. In addition, the method includes providing, by the services platform, access to the degree of relatedness via a user interface.
Absstract of: WO2025121789A1
The present invention relates to an inflammatory bowel disease model derived from induced pluripotent stem cells and a method for producing same. The inflammatory bowel disease model simulates stable intestinal epithelial cells from induced pluripotent stem cells and remarkably exhibits the expression of inflammation-related genes according to the occurrence and improvement of inflammatory bowel disease, and thus can be effectively used for evaluating the efficacy of a drug for treating inflammatory bowel disease.
Nº publicación: CN120129835A 10/06/2025
Applicant:
KEIO OKI
\u5E86\u5E94\u4E49\u587E
Absstract of: CN120129835A
Provided are: a method for detecting an immune-mediated inflammatory disease characterized by an increase in expression of MMP12 in a subject; a diagnostic reagent containing a substance that specifically interacts with MMP12; and a therapeutic agent containing a substance that inhibits MMP12.
BOPI
Electronic site
